AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03920176 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: ASSIGN Score
Description: ASSIGN Cardiovascular Risk Score
Study NCT00535691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Ointment 0.03%
Description: Twice daily, 14 days treatment.
Study NCT00535691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Ointment 0.03%
Description: Once daily, 14 days treatment.
Study NCT01136863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Felodipine
Study NCT01136863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00723671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT00886106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Remifentanil (Ultiva®; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to circa 0.7 µg kg-1 min-1
Study NCT00886106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied intravenously as active placebo at a dose of 15 µg kg-1 min-1 over 5 minutes to mimic typical central nervous side effects of remifentanil
Study NCT03527316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: 125 mg MDMA per os, single dose
Study NCT03527316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules containing mannitol looking identical to the other drugs.
Study NCT00000936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Cyclosporine
Description: Administered orally as either sandimmune or neoral at a dose determined by weight. Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
Study NCT00000936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Cyclosporine
Description: Administered orally as either sandimmune or neoral at a dose determined by weight. Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
Study NCT02221947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, single dose via intravenous infusion over 1 hour.
Study NCT03736733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity program
Description: Two weekly exercise sessions at the university hospital of St-Etienne for 1 month then relay outside in a sports association or club certified Sports Health in the Loire (42) or Haute-Loire (43) for 2 months.
Study NCT01917890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of BCM95 Curcumin (as 6 × 500 mg capsules)
Study NCT04365686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol as induction agent
Description: Patients who received propofol (2mg/kg) only at the induction of general anesthesia.
Study NCT02056444 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Study NCT01917890 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.~Patients take 3 grams of roasted rice powder (as 6 × 500 mg capsules)
Study NCT03736733 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Advice and recommendations of physical activity at home
Description: Advice and recommendations of physical activity at home (= current clinical practice, from 1 to 3 sessions per week in autonomy).
Study NCT03944421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red and Processed Meat
Description: Integration of 240 grams (raw weight) of red and processed meat into daily diet for 2 week period.
Study NCT02056444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Study NCT01016067 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INFUSE/MASTERGRAFT
Description: INFUSE® (rhBMP-2) on an absorbable collagen sponge (ACS) and MASTERGRAFT® granules with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
Study NCT03944421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quorn
Description: Integration of 240 grams (uncooked weight) of Quorn into daily diet for 2 week period.
Study NCT03757325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DNL747
Description: DNL747
Study NCT03772340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tradipitant
Description: Oral capsule
Study NCT03772340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study NCT01661309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inactive lozenge
Description: Manufactured to mimic 1mg methylcobalamin lozenge
Study NCT01661309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inactive lozenge
Description: Manufactured to mimic 1mg methylcobalamin lozenge
Study NCT01661309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Methylcobalamin
Description: Aimed at reducing plasma tHcy.
Study NCT01661309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methylcobalamin
Description: Aimed at reducing plasma tHcy.
Study NCT03419000 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: blood sample
Description: Seven blood samples (4 ml each on 5 EDTA and 2 dry tubes) will be collected in each patient/ healthy volunteers subject to determine the expression profile of miRNAs in the plasma as well as in the exosomes
Study NCT03419000 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: Seven blood samples (4 ml each on 5 EDTA and 2 dry tubes) will be collected in each patient/ healthy volunteers subject to determine the expression profile of miRNAs in the plasma as well as in the exosomes
Study NCT04390789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical Single visit Retreatment
Description: Non-surgical endodontic retreatment will be carried out in single visit.
Study NCT04390789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multi visit Retreatment with calcium hydroxide dressing
Description: In this group,GP removal and biomechanical preparation will be carried out in first visit,after which calcium hydroxide dressing will be placed and temporarily restored.after 7 days,in second visit obturation will be done followed by permanent restoration
Study NCT00606853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Rewards valued $1-$100 for abstinence or treatment attendance
Study NCT00000936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Cyclosporine
Description: Administered intravenously (IV) both during and after transplantation at a dosage determined by individual age.
Study NCT03980626 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: The exercise intervention is designed to improve cardiorespiratory fitness, a known correlate of cognition and brain health, and follows the American College of Sports Medicine exercise guidelines for cancer survivors. Participants will engage in small group, moderate-to-vigorous intensity walking sessions three times weekly. Sessions will begin with a warm-up and end with a cool down and be progressive in nature. Volume of exercise will increase across weeks such that participants will progress from 15-20 minutes of walking to 40-45 minutes by week 8, and from 40-55% of their estimated heart rate reserve (HRR) to 65% of their HRR by week 9. All sessions will be led by trained exercise specialists to ensure close monitoring of participant safety. Participants will wear heart rate monitors and be asked to rate their perceived exertion to ensure they are exercising within the prescribed range. Modifications to each participant's exercise prescription will be made as needed.
Study NCT01631292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 600 IU Vitamin D3
Description: Once daily
Study NCT01631292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 2000 IU Vitamin D3
Description: Once daily
Study NCT01631292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4000 IU Vitamin D3
Description: Once daily
Study NCT03733457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-assisted Stepped-care
Description: Step 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
Study NCT01353755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grass pollen specific immunotherapy
Description: * Strength 1 (0.78μg/mL)~* Strength 2 (6.25μg/mL)~* Strength 3 (50μg/mL)~* Strength 4 (200μg/mL)~The subcutaneous injections will be administered at intervals of 7 (+ 7 days)during up-titration. For maintenance the injection intervals are prolonged to 4 weeks (+2). The double blind treatment period is 2 years, followed by 1 year open-label treatment for patients previously treated with verum and 3 years open-label treatment for patients previously recieved placebo.
Study NCT01353755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placabo
Description: Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
Study NCT01268943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
Study NCT01268943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
Study NCT01016067 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autograft bone
Description: Autogenous bone graft with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
Study NCT03199794 — intervention group
Intervention type: BIOLOGICAL
Intervention: OBIZUR
Description: Treating physician will determine treatment regimen and frequency of laboratory and clinical assessments according to routine clinical practice.
Study NCT01268943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral pills, 1400mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
Study NCT01268943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
Study NCT01184456 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GanedenBC30, GBI-30, PTA-6086
Description: 1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.
Study NCT01184456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule per day for 90 days.
Study NCT01758211 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI Navigation AVM resection
Description: intraoperative fMRI navigation guided resection in AVM patients
Study NCT01758211 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional resection
Description: conventional resection in AVM patients
Study NCT04155658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Toothpaste containing 1450ppm SMFP
Description: Experimental Toothpaste containing 1450ppm SMFP
Study NCT04155658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothpaste containing 1450ppm SMFP
Description: Toothpaste containing 1450ppm SMFP
Study NCT04155658 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Toothpaste with no fluoride
Description: Toothpaste with no fluoride
Study NCT01266889 — intervention group
Intervention type: DEVICE
Intervention: device:INVOS 5100
Description: Continuous wave NIRS is a method for measurement of cerebral oxygenation and haemodynamics. This method is non-invasive, continuous, and can also be used as bedside monitoring. With continuous wave NIRS only changes in concentration of oxyhaemoglobin (O2Hb) and deoxyhaemoglobin (HHb) can be measured, not the absolute level of these parameters. It has been shown that changes in concentration of HbD (O2Hb - HHb) reflect changes in CBF. So, continuous monitoring of changes in concentration of HbD can be used as an indicator of changes in CBF, but changes in CBV will also influence the HbD signal, as will changes in arterial O2 saturation (saO2) and changes in cerebral metabolic rate for oxygen.
Study NCT02301754 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INVAC-1
Description: intradermal injection combined with electroporation
Study NCT02226978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipranavir
Study NCT02226978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study NCT02226978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Study NCT01825330 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS and cognitive stimulation
Description: Synchronized TMS and cognitive stimulation to 6 brain areas.
Study NCT01825330 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Study NCT04683406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273 600 mg
Description: 3 X 200-mg tablet taken orally
Study NCT04683406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Oseltamivir
Description: Placebo capsules matching oseltamivir2 X 75-mg
Study NCT04683406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Oseltamivir
Description: Placebo capsules matching oseltamivir2 X 75-mg
Study NCT03757325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT03070028 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: crystallised phenol
Description: crystallised phenol will be applied to sinus cavity
Study NCT04683406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir(oral)
Description: 2 X 75-mg tablet taken orally
Study NCT04683406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to ZSP1273
Description: Placebo capsules matching ZSP1273 600 mg
Study NCT04683406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to ZSP1273
Description: Placebo capsules matching ZSP1273 600 mg
Study NCT02523989 — intervention group
Intervention type: OTHER
Intervention: study group
Description: Explore the relationship of heavy metals and health related quality of life, including the relationship between the developmental delays and polymorphism of arsenic methylation enzymes, arsenic methylation capability and blood metals. Identify the interaction of children function, health condition, and quality of life and arsenic methylation and blood metals in children with developmental delays.
Study NCT02170038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgynon
Description: Subjects will receive 21 daily oral doses of Microgynon tablets containing 0.15 mg levonorgestrel und 0.03 mg ethinylestradiol.
Study NCT02170038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Noristerat(BAY86-6308)
Description: Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.
Study NCT02877667 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: planar acoustic wave device
Description: accessory to laser treatment
Study NCT05000879 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMB for Moms
Description: 12-week program that emphasizes mindfulness and cognitive behavioral skills
Study NCT02513511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laryngoscopy under hypnosis
Description: patient will be put in an hypnotic state before performing a laryngoscopy followed by oro-tracheal intubation
Study NCT01206049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1,000 mg/m2 on day 1 of a 2 weeks cycle
Study NCT01206049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 60 mg/m2 on day 1 of a 2 weeks cycle
Study NCT01206049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1,000 mg/m2 x 2 daily on days 1-7 of a 2 weeks cycle
Study NCT01206049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: 6 mg/kg on day 1 of a 2 weeks cycle
Study NCT01206049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg on day 1 of a 2 weeks cycle
Study NCT03514849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prophylactic cranial irradiation (PCI)
Description: Patients in the control group are enrolled in the follow-up, and the patients in research group will receive prophylactic cranial irradiation （PCI） by 25 gy/10 fx.
Study NCT03514849 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: lobectomy + mediastinal lymph node dissection or systematic lymph node sampling
Description: lobectomy + mediastinal lymph node dissection or systematic lymph node sampling
Study NCT03514849 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lobectomy + mediastinal lymph node dissection or systematic lymph node sampling
Description: lobectomy + mediastinal lymph node dissection or systematic lymph node sampling
Study NCT03514849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: postoperative adjuvant chemotherapy
Description: If the postoperatively pathological examination of the patient is confirmed to be in pT1-2N0 stage, a single postoperative adjuvant chemotherapy (combining etoposide with cisplatin) is recommended. If patients are difficult to tolerate the side effects of cisplatin, we can replace cisplatin by carboplatin in the adjuvant chemotherapy scheme.
Study NCT03514849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: postoperative adjuvant chemotherapy
Description: If the postoperatively pathological examination of the patient is confirmed to be in pT1-2N0 stage, a single postoperative adjuvant chemotherapy (combining etoposide with cisplatin) is recommended. If patients are difficult to tolerate the side effects of cisplatin, we can replace cisplatin by carboplatin in the adjuvant chemotherapy scheme.
Study NCT00258050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Subjects will receive midazolam by oral or IV route on Days 1, 3, 9 and 11. Oral midazolam was supplied as 3 mg tablets; IV midazolam was supplied as 1 milligram per milliliter (mg/L) sterile solution.
Study NCT00258050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Subjects will receive 1500 mg lapatinib by oral route once daily from Day 4.
Study NCT02894281 — intervention group
Intervention type: DEVICE
Intervention: pupillary light reflex
Description: measure with infra-red cameras
Study NCT02968836 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Blend of amino acids
Description: The product was poured in bottles containing the enteral nutrition that the patient received as standard of care.
Study NCT04660175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-resistance therapy
Description: The non-resistance technique, created in Jaseng Hospital, is a combination of ischemic compression and mobilization It is a treatment that improves the limited range of motion of the cervical spine and relieves pain by applying ischemic pressure to the induration of the neck and at the same time firmly supporting the patient's head to give passive joint movements and completely relax.
Study NCT04420910 — intervention group
Intervention type: OTHER
Intervention: Non-Motor Symptoms
Description: NMSs of the participants were evaluated using the Non-Motor Symptoms Scale (NMSS). The scale consists of 30 yes-no questions and is administered face to face with the therapist.
Study NCT04660175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: According to the judgment of the oriental medicine doctor, select acupuncture point and tender spots such as BL10, TE14, GB20, GV16, etc. to a depth of 10 mm 6 -Self needle in 12 blood spots.
Study NCT04660175 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: According to the judgment of the oriental medicine doctor, select acupuncture point and tender spots such as BL10, TE14, GB20, GV16, etc. to a depth of 10 mm 6 -Self needle in 12 blood spots.
Study NCT04660175 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chuna
Description: Chuna treatment is administered once a day during the hospitalization period. Chuna is Korean manual therapy using methods such as joint mobilization, joint distraction, fascia relaxation and manipulation.